DNAJB5 (DnaJ Heat Shock Protein Family Member B5)

title: DNAJB5 Gene

DNAJB5 (DnaJ Heat Shock Protein Family Member B5)

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | DNAJB5 |
| Full Name | DnaJ Heat Shock Protein Family (Hsp40) Member B5 |
| Chr Location | 9p13.3 |
| NCBI Gene ID | 25822 |
| OMIM ID | 608591 |
| Ensembl ID | ENSG00000135919 |
| UniProt ID | O75164 |
| Encoded Protein | DNAJB5 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Cancer |

</div>

Overview

DNAJB5 (DnaJ Heat Shock Protein Family Member B5), also known as Hsp40 or DNAB5, is a member of the DnaJ/Hsp40 family of molecular chaperones. Located on chromosome 9p13.3, DNAJB5 functions as a co-chaperone that assists Hsp70 proteins in protein folding, refolding, and clearance of misfolded proteins [1][2].

The DNAJ/Hsp40 family is characterized by the presence of a highly conserved J-domain, which enables interaction with Hsp70 chaperones and stimulates their ATPase activity.[@he2022] This interaction is crucial for protein quality control mechanisms that prevent the accumulation of toxic protein aggregates—a hallmark of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [2][3].

DNAJB5 has attracted attention for its potential role in preventing protein aggregation in neurodegenerative diseases, where it may help mitigate the accumulation of misfolded proteins such as amyloid-beta, tau, and alpha-synuclein [1][2][@he2022].

title: DNAJB5 Gene

DNAJB5 (DnaJ Heat Shock Protein Family Member B5)

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | DNAJB5 |
| Full Name | DnaJ Heat Shock Protein Family (Hsp40) Member B5 |
| Chr Location | 9p13.3 |
| NCBI Gene ID | 25822 |
| OMIM ID | 608591 |
| Ensembl ID | ENSG00000135919 |
| UniProt ID | O75164 |
| Encoded Protein | DNAJB5 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Cancer |

</div>

Overview

DNAJB5 (DnaJ Heat Shock Protein Family Member B5), also known as Hsp40 or DNAB5, is a member of the DnaJ/Hsp40 family of molecular chaperones. Located on chromosome 9p13.3, DNAJB5 functions as a co-chaperone that assists Hsp70 proteins in protein folding, refolding, and clearance of misfolded proteins [1][2].

The DNAJ/Hsp40 family is characterized by the presence of a highly conserved J-domain, which enables interaction with Hsp70 chaperones and stimulates their ATPase activity.[@he2022] This interaction is crucial for protein quality control mechanisms that prevent the accumulation of toxic protein aggregates—a hallmark of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [2][3].

DNAJB5 has attracted attention for its potential role in preventing protein aggregation in neurodegenerative diseases, where it may help mitigate the accumulation of misfolded proteins such as amyloid-beta, tau, and alpha-synuclein [1][2][@he2022].

Molecular Structure and Biochemistry

Protein Architecture

DNAJB5 encodes a protein with distinct functional domains:

• J-Domain (1-70 aa): The defining feature of DNAJ proteins, containing the conserved HPD motif
• Gly/Phe-Rich Region (70-150 aa): Flexible linker region
• C-terminal Substrate-Binding Domain (150-320 aa): Binds client proteins for targeting to Hsp70

The J-Domain Protein Family

DNAJB5 belongs to the DNAJ subfamily, which includes proteins with a full J-domain structure:

| Subfamily | Characteristics | Examples |
|-----------|-----------------|----------|
| DNAJA | Contain J-domain + Gly/Phe-rich + C-terminal | DNAJA1 (Hsp40), DNAJA2 |
| DNAJB | Contain J-domain + variable C-terminal | DNAJB5, DNAJB6, DNAJB8 |
| DNAJC | Contain J-domain + additional domains | DNAJC3, DNAJC13 |

Mechanism of Action

DNAJB5 functions through:

Physiological Functions

Protein Folding Assistance

DNAJB5, in collaboration with Hsp70 family members, facilitates proper protein folding:

• Co-translational folding assistance
• Post-translational quality control
• Prevention of misfolding during stress

Protein Quality Control

The DNAJB5-Hsp70 complex provides essential quality control functions [2][3]:

• Proteasomal Degradation: Targets ubiquitinated misfolded proteins for degradation
• Autophagic Clearance: Routes aggregates to autophagosomes
• Aggregate Disassembly: Works with disaggregases to reverse aggregation

Stress Response

DNAJB5 expression is regulated by cellular stress:

• Heat Shock Response: Upregulated under heat shock conditions
• Oxidative Stress: Induced by reactive oxygen species
• Proteotoxic Stress: Increased accumulation of misfolded proteins

Role in Neurodegenerative Diseases

Alzheimer's Disease

DNAJB5 has been implicated in Alzheimer's disease pathogenesis through its role in protein quality control [1][2]:

• Amyloid-Beta Metabolism: May influence amyloid-beta production or clearance
• Tau Pathology: Potential involvement in tau aggregation and clearance
• Proteostasis Maintenance: Helps maintain neuronal proteostasis under stress

Parkinson's Disease

In Parkinson's disease, alpha-synuclein aggregation is a key pathological feature [1][2]. Research has shown that:

• DNAJ proteins can interact with alpha-synuclein
• Hsp40 overexpression reduces alpha-synuclein toxicity
• DNAJ family members influence aggregation kinetics

Amyotrophic Lateral Sclerosis (ALS)

ALS is characterized by protein aggregation including TDP-43 and FUS [2][3]:

• DNAJB5 expression is altered in ALS models
• DNAJ proteins may help prevent toxic aggregation
• Chaperone dysfunction may contribute to disease progression

Protective Mechanisms

DNAJ proteins provide neuroprotection through multiple mechanisms [3][4]:

Therapeutic Implications

Chaperone-Targeted Therapies

DNAJB5 represents a potential therapeutic target for neurodegenerative diseases [4]:

• Small Molecule Activators: Compounds that enhance DNAJB5 activity
• Gene Therapy: Viral delivery of DNAJB5 to neurons
• Protein-Based Therapies: Recombinant DNAJB5 administration

Protein Disaggregases

The development of engineered protein disaggregases based on Hsp40-Hsp70-Hsp110 complexes represents a promising therapeutic approach [4]. These designer disaggregases could potentially reverse protein aggregation in neurodegenerative diseases.

Expression Pattern

Tissue Distribution

DNAJB5 exhibits broad tissue expression with notable brain localization:

• Highest Expression: Hippocampus, cerebral cortex, cerebellum
• Moderate Expression: Testis, ovary, heart
• Cellular Localization: Cytosolic and membrane-associated

Brain Region Expression

Within the brain, DNAJB5 is expressed in:

• Hippocampal neurons (CA1-CA3 pyramidal cells)
• Cortical layer 2-4 neurons
• Cerebellar Purkinje cells
• Substantia nigra dopaminergic neurons

Regulation

DNAJB5 expression is regulated by:

• Heat shock factor (HSF1)-dependent transcription
• Cellular stress conditions
• Developmental stage

Protein-Protein Interactions

Hsp70 Family Members

DNAJB5 interacts with multiple Hsp70 family proteins [9][10]:

• HSPA1A (Hsp70-1): Major stress-inducible Hsp70
• HSPA8 (Hsc70): Constitutively expressed chaperone
• HSPA4 (Hsp110): Co-chaperone for disaggregation
• HSPA5 (BiP/Grp78): ER-resident chaperone
• HSPA9 (Mortalin): Mitochondrial Hsp70

Hsp90 Interaction

DNAJB5 can also interface with Hsp90 chaperone system:

• Hsp90 client protein quality control
• Coordination between Hsp70 and Hsp90 systems
• Shared substrate targeting mechanisms

Other DNAJ Proteins

DNAJB5 may cooperate with other DNAJ family members [11]:

• DNAJB1 (Hsp40): Canonical Hsp40 co-chaperone
• DNAJB6: Brain-enriched Hsp40 with aggregation suppression
• DNAJB8: Testis-specific Hsp40
• DNAJC family members for broader proteostasis network

Mechanistic Role in Neurodegeneration

Protein Aggregation Pathways

The aggregation of misfolded proteins follows a characteristic cascade [3][4][12]:

DNAJB5 intervenes at multiple points in this cascade:

• Prevents initial misfolding through folding assistance
• Captures early oligomers before they become nucleation-competent
• Routes aggregates to degradation pathways
• Works with disaggregases to reverse early fibril formation

Aggregate Clearance Mechanisms

DNAJB5 participates in multiple clearance pathways [13][14]:

Proteasomal Degradation (Ubiquitin-Proasome System):

• Recognizes ubiquitinated misfolded proteins
• Delivers substrates to the 26S proteasome
• Facilitates unfolding and translocation into the proteasome
• Works with Hsp70 to remove steric blocks

• Chaperone-mediated autophagy (CMA): Direct delivery to lysosomes via LAMP-2A
• Macroautophagy: Bulk sequestration of aggregates into autophagosomes
• Endosomal microautophagy: Selective uptake at endosomal membranes

• Export to extracellular space
• Sequestration into aggresomes for controlled storage

Membrane Protection and Repair

DNAJB5 contributes to membrane integrity [4]:

• Associates with damaged membranes
• Prevents aggregation of membrane-associated proteins
• Aids in membrane fusion/fission events
• Supports synaptic vesicle recycling

Role in Specific Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, DNAJB5 may modulate multiple pathological processes [1][2][15]:

Amyloid-Beta Metabolism:

• May influence APP processing and Aβ production
• Potential effects on α-secretase processing
• Clearance of Aβ aggregates through proteostasis
• Interaction with AChE and other Aβ-interacting proteins

• Tau is an Hsp70 client protein
• DNAJB5 may assist in tau refolding/degradation
• Modulation of tau phosphorylation states
• Prevention of tau aggregate formation

• Critical for synaptic protein quality control
• Supports AMPA receptor trafficking
• Maintains neurotransmitter release machinery
• Preserves synaptic plasticity under stress

• Modulates heat shock response in glia
• May regulate inflammatory cytokine expression
• Supports neuronal survival in inflammatory environments

Parkinson's Disease

In Parkinson's disease, alpha-synuclein aggregation is central [1][16]:

Alpha-Synuclein Homeostasis:

• DNAJ proteins including DNAJB5 interact with α-synuclein
• Prevents α-synuclein oligomerization
• May slow fibril extension kinetics
• Supports autophagic clearance of α-synuclein

• High metabolic demand increases proteostatic stress
• Mitochondrial dysfunction amplifies protein damage
• DNAJB5 helps maintain proteostasis under these conditions
• May provide neuroprotection in SN neurons

• LRRK2 mutations are common in familial PD
• Hsp40 proteins may modulate LRRK2 aggregation
• Potential therapeutic modulation strategies
• Interaction with other PD-associated proteins

Amyotrophic Lateral Sclerosis (ALS)

ALS features protein aggregation in motor neurons [2][3]:

TDP-43 Pathology:

• TDP-43 is a major aggregating protein in ALS
• DNAJ proteins may modulate TDP-43 aggregation
• Hsp40 family members show altered expression in ALS
• Potential for therapeutic intervention

• FUS is another aggregating protein in ALS
• Hsp40 proteins can interact with FUS
• DNAJB5 may modulate FUS aggregation
• Related to RNA processing dysfunction

• Most common genetic cause of ALS/FTD
• Produces toxic dipeptide repeats
• DNAJ proteins may counteract this toxicity
• Potential for modifier-based therapy

Huntington's Disease

Huntington's disease involves mutant huntingtin aggregation [17][18]:

Huntingtin Quality Control:

• Mutant huntingtin has expanded polyglutamine tract
• DNAJB5 can triage mutant huntingtin aggregates
• Prevents toxic oligomer formation
• Routes to degradation pathways

• Slows nucleation phase
• Reduces fibril growth rate
• Decreases overall aggregate burden
• Maintains proteostasis longer

Therapeutic Strategies

Small Molecule Approaches

Hsp70/Hsp40 Modulators:

• Agonists that enhance chaperone activity
• Compounds that increase DNAJB5 expression
• Allosteric activators of J-domain function

• Support Hsp110-Hsp70-Hsp40 system
• Increase aggregate dissolution rates
• Synergy with autophagy induction

Gene Therapy Approaches

Viral Vector Delivery:

• AAV-mediated DNAJB5 overexpression
• Targeting specific brain regions
• Cell type-specific promoters
• Regulated expression systems

• Enhance endogenous DNAJB5 expression
• Modify regulatory elements
• Optimize codon usage for better translation

Protein-Based Therapies

Recombinant Protein Delivery:

• Purified DNAJB5 protein administration
• Engineered variants with enhanced activity
• Cell-penetrating variants
• Targeted delivery to neurons

• J-domain peptides for Hsp70 activation
• Substrate-binding domain fragments
• Cell-permeable chaperone mimetics

Combination Strategies

Chaperone + Degradation:

• Combine DNAJB5 enhancement with proteasome/ autophagy activators
• Coordinated clearance of existing aggregates
• Prevention of new aggregate formation

• Small molecule aggregation inhibitors
• Antibody-based approaches
• Multi-target combination therapy

Research Methods and Tools

Protein-Protein Interaction Studies

• Co-immunoprecipitation: Identify DNAJB5 interacting partners
• Yeast two-hybrid screening: Map interaction domains
• Surface plasmon resonance: Measure binding affinities
• Fluorescence resonance energy transfer (FRET): Monitor complex formation in cells

Aggregation Assays

• Thioflavin T fluorescence: Quantify fibril formation
• Electron microscopy: Visualize aggregate structures
• Atomic force microscopy: Measure aggregate morphology
• Sedimentation assays: Separate soluble from aggregated protein

Cellular Models

• Neuronal cell lines: SH-SY5Y, PC12, N2a
• Primary neuron cultures: Mouse cortical neurons
• iPSC-derived neurons: Patient-specific models
• Organoid systems: Brain organoids for complex models

Animal Models

• Transgenic mice: Models of protein aggregation diseases
• Knockout mice: DNAJB5 loss-of-function studies
• Viral transduction: Local overexpression in brain
• Behavioral testing: Cognitive and motor assessments

Evolutionary Conservation

Species Distribution

DNAJB5 is evolutionarily conserved across eukaryotes:

| Species | Homolog | Conservation |
|---------|---------|--------------|
| Human | DNAJB5 | Reference |
| Mouse | Dnajb5 | Very high (95%+) |
| Zebrafish | dnajb5 | High |
| D. melanogaster | dnaJ-1 | Moderate |
| C. elegans | dnj-10 | Moderate |
| S. cerevisiae | YDJ1 | Lower |

Functional Conservation

Key functional domains are highly conserved:

• J-domain: Nearly identical across species
• Gly/Phe-rich region: Variable but present
• C-terminal domain: Moderately conserved

Genetic Variations and Polymorphisms

Known Variants

DNAJB5 genetic variations have been studied:

• SNPs: Various single nucleotide polymorphisms identified
• Population frequency: Common variants in population databases
• Functional effects: Most variants have mild effects
• Disease associations: Limited direct evidence

Clinical Significance

Currently, DNAJB5 variants are not strongly associated with:

• Rare monogenic diseases
• Strong risk factors for complex diseases
• Pharmacogenomic considerations

• Neurodegenerative disease progression
• Response to chaperone-based therapies
• Protein aggregation disease severity

Future Directions

Research Gaps

Emerging Approaches

See Also

• [Molecular Chaperones](/proteins/molecular-chaperones)
• [Hsp70 Protein Family](/proteins/hsp70-protein)
• [Protein Aggregation Mechanism](/mechanisms/protein-aggregation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS (Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [Proteostasis](/mechanisms/proteostasis)

External Links

• [NCBI Gene: DNAJB5](https://www.ncbi.nlm.nih.gov/gene/25822)
• [UniProt: O75164](https://www.uniprot.org/uniprot/O75164)
• [OMIM: 608591](https://www.omim.org/entry/608591)
• [Ensembl: ENSG00000135919](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135919)

References